Q32 Bio Inc. (QTTB)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Q32 Bio Inc. (QTTB) trades at $13.60 with AI Score 65/100 (Grade B+). Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologic therapeutics for autoimmune and inflammatory diseases. Market cap: $173.76M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026QTTB stock analysis for 2026: Analysts have set a consensus price target of $13.00 for Q32 Bio Inc., suggesting 4.4% downside from the current price of $13.60. The AI MoonshotScore is 65/100, indicating a bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
QTTB: 1/1 perspectives are bullish.
How is this calculated? →Q32 Bio Inc. (QTTB) Healthcare & Pipeline Overview
Q32 Bio Inc. is a clinical-stage biotechnology company specializing in biologic therapeutics for autoimmune and inflammatory diseases. Its pipeline features ADX-097, targeting complement-mediated diseases, and Bempikibart (ADX-914), currently in Phase II trials for dermatological conditions, positioning it within the competitive biotechnology landscape.
What Is the Investment Thesis for QTTB?
Q32 Bio Inc. presents a focused investment opportunity within the biotechnology sector, driven by its clinical-stage pipeline targeting autoimmune and inflammatory diseases. Key value drivers include the successful advancement of ADX-097 through clinical trials for complement-mediated diseases and the progression of Bempikibart (ADX-914) in Phase II trials for dermatological conditions. The company's high gross margin of 99.5% indicates strong potential profitability upon commercialization. Upcoming clinical trial results for both ADX-097 and Bempikibart serve as potential catalysts. However, the company's relatively small market capitalization of $173.76M and negative beta of -1.02 suggest higher volatility and sensitivity to market downturns. Successful navigation of regulatory hurdles and securing partnerships will be crucial for long-term growth.
Based on FMP financials and quantitative analysis
QTTB Key Highlights
- Market capitalization of $173.76M, reflecting its position as a smaller player in the biotechnology industry.
- P/E ratio of 2.3, suggesting potential undervaluation relative to earnings.
- Profit margin of 61.9%, indicating strong profitability from its operations.
- Gross margin of 99.5%, highlighting efficient cost management in its research and development activities.
- Beta of -1.02, suggesting an inverse correlation with the market, potentially offering diversification benefits.
Who Are QTTB's Competitors?
QTTB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | $645.84 | -1.29% | $66.54B | 91 |
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| LLY Eli Lilly and Company | $1202.56 | -0.94% | $1.13T | 98 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are QTTB's Key Strengths?
- Innovative pipeline of biologic therapeutics.
- Focus on high unmet medical needs.
- High gross margin.
- Experienced management team.
What Are QTTB's Weaknesses?
- Clinical-stage company with no approved products.
- Reliance on successful clinical trial outcomes.
- Limited financial resources.
- Small market capitalization.
What Could Drive QTTB Stock Higher?
- Clinical trial results for ADX-097 in complement-mediated diseases.
- Clinical trial results for Bempikibart (ADX-914) in atopic dermatitis and alopecia areata.
- Potential for strategic partnerships with larger pharmaceutical companies.
- Advancements in the development of their proprietary technology platform.
What Are the Key Risks for QTTB?
- Failure to obtain regulatory approval for ADX-097 and Bempikibart.
- Competition from established pharmaceutical companies with greater resources.
- Patent expiration and the emergence of biosimilar competition.
- Adverse events or unexpected safety concerns in clinical trials.
- Dependence on securing additional funding to support ongoing research and development activities.
What Are the Growth Opportunities for QTTB?
- Advancement of ADX-097 for Complement-Mediated Diseases: ADX-097, Q32 Bio's lead product candidate, targets a range of complement-mediated diseases, including lupus nephritis and IgA nephropathy. The market for lupus nephritis treatment alone is projected to reach billions of dollars. Successful completion of clinical trials and regulatory approval could drive significant revenue growth, positioning Q32 Bio as a key player in this therapeutic area. Timeline for potential market entry is dependent on clinical trial outcomes and regulatory review.
- Development of Bempikibart (ADX-914) for Atopic Dermatitis and Alopecia Areata: Bempikibart is currently in Phase II clinical trials for atopic dermatitis and alopecia areata. The atopic dermatitis market is expected to grow substantially, driven by increasing prevalence and unmet needs. Positive clinical trial results and subsequent regulatory approval could open up a significant market opportunity for Q32 Bio. The timeline for commercialization depends on the success of ongoing trials and regulatory processes.
- Expansion of Pipeline through Strategic Partnerships and Acquisitions: Q32 Bio can expand its pipeline by in-licensing or acquiring promising drug candidates or technologies. Strategic partnerships with other biotechnology or pharmaceutical companies can provide access to new therapeutic areas and accelerate the development of existing programs. This approach can diversify the company's risk profile and create new growth opportunities. The timing and success of such initiatives are contingent on market conditions and available opportunities.
- Geographic Expansion Beyond the United States: Currently, Q32 Bio operates primarily in the United States. Expanding into international markets, such as Europe and Asia, could significantly increase its addressable market. This expansion would require navigating different regulatory environments and establishing partnerships with local distributors or pharmaceutical companies. The timeline for international expansion depends on the company's strategic priorities and available resources.
- Leveraging Proprietary Technology Platform for New Drug Discovery: Q32 Bio's expertise in developing biologic therapeutics for autoimmune and inflammatory diseases can be leveraged to discover and develop new drug candidates. By utilizing its proprietary technology platform, the company can identify novel targets and develop innovative therapies for unmet medical needs. This approach can create a sustainable pipeline of new products and drive long-term growth. The success of this strategy depends on the company's research and development capabilities and its ability to identify promising new targets.
What Opportunities Does QTTB Have?
- Positive clinical trial results for ADX-097 and Bempikibart.
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
- Increasing prevalence of autoimmune and inflammatory diseases.
What Threats Does QTTB Face?
- Failure to obtain regulatory approval for their drug candidates.
- Competition from established pharmaceutical companies.
- Patent expiration and biosimilar competition.
- Adverse events in clinical trials.
What Are QTTB's Competitive Advantages?
- Proprietary technology platform for developing biologic therapeutics.
- Strong intellectual property protection for their drug candidates.
- Clinical trial data demonstrating the safety and efficacy of their therapies.
- Expertise in targeting complement-mediated diseases and dermatological conditions.
What Does QTTB Do?
Founded in 2017 and based in Waltham, Massachusetts, Q32 Bio Inc. is dedicated to restoring healthy immune balance in patients suffering from autoimmune and inflammatory diseases. Originally named AdMIRx Inc., the company rebranded in April 2020 to Q32 Bio Inc. The company focuses on addressing pathological immune dysfunction through the development of biologic therapeutics. Their lead product candidate, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to restore complement regulation. ADX-097 has completed Phase I clinical trials and is being developed for renal and other complement-mediated diseases with high unmet needs, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. Q32 Bio is also advancing Bempikibart (ADX-914), a fully human anti-interleukin-7 receptor alpha antagonist monoclonal antibody. Bempikibart aims to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin. This product is currently in Phase II clinical trials for the treatment of atopic dermatitis and alopecia areata. Q32 Bio operates primarily in the United States.
What Products and Services Does QTTB Offer?
- Develop biologic therapeutics for autoimmune and inflammatory diseases.
- Focus on restoring healthy immune balance in patients.
- Advance ADX-097, a humanized anti-C3d monoclonal antibody fusion protein, for complement-mediated diseases.
- Develop Bempikibart (ADX-914), a fully human anti-interleukin-7 receptor alpha antagonist monoclonal antibody, for atopic dermatitis and alopecia areata.
- Conduct Phase I and Phase II clinical trials to evaluate the safety and efficacy of their drug candidates.
- Target diseases with high unmet medical needs, such as lupus nephritis and IgA nephropathy.
How Does QTTB Make Money?
- Develop and commercialize biologic therapeutics.
- Generate revenue through the sale of approved drugs.
- Out-license or partner with other companies for drug development and commercialization.
- Secure funding through venture capital, public offerings, and grants.
What Industry Does QTTB Operate In?
Q32 Bio Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for autoimmune and inflammatory disease therapeutics is substantial and growing, driven by an aging population and increasing prevalence of these conditions. Key trends include the development of novel biologic therapies and personalized medicine approaches. Q32 Bio's focus on complement-mediated diseases and dermatological conditions positions it within specific niches of this broader market, competing with both large pharmaceutical companies and smaller biotech firms.
Who Are QTTB's Key Customers?
- Patients with autoimmune and inflammatory diseases.
- Healthcare providers who prescribe and administer their drugs.
- Hospitals and clinics that use their therapies.
- Pharmaceutical companies that may partner with them for drug development and commercialization.
How Q32 Bio Inc. Is Valued
Q32 Bio Inc. carries a market capitalization of $173.76M, placing it in the micro-cap category. Relative to its peer group, QTTB's quantitative score of 65/100 is below the peer average of 86/100.
Company Profile
Q32 Bio Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Waltham, US. The company is led by CEO Jodie Pope Morrison. QTTB has traded publicly since 2018.
ROE 231%Key Financial Metrics
Return on equity for Q32 Bio Inc. stands at 230.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 52.2%, showing how much profit it generates from its asset base. QTTB trades at a trailing price-to-earnings ratio of 2.28, below the Healthcare sector average of ~23x. Its free cash flow yield is -17.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.36 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 19.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 5/9Financial Health
Q32 Bio Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.96 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Q32 Bio Inc. revenue of about $1.3M for fiscal 2026, with EPS near $-1.82. The estimate reflects 5 contributing analysts.
Net buyingInsider Activity
Over the past six months, Q32 Bio Inc. insiders filed 13 SEC Form 4 transactions — 3 sales and 10 purchases. On net that is roughly 4.0M shares acquired (about $30.1M) — insiders putting money in tends to read as conviction.
QTTB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Q32 Bio's growth potential, indicating that leadership believes in the company's future.
- Community sentiment has shifted positively, with discussions highlighting recent advancements in their biotech innovations.
- Analysts are increasingly optimistic about Q32's pipeline, particularly in immunotherapy, which is gaining traction in the market.
- The company has secured new partnerships that could enhance its research capabilities and market reach, fostering investor interest.
Bear Case
- Concerns about the competitive landscape in the biotech sector have emerged, with many players vying for similar therapeutic areas.
- Social sentiment shows skepticism regarding the timeline for product development, with some investors questioning the feasibility of their goals.
- Recent regulatory challenges in the biotech space have raised alarms, leading to a cautious outlook among some community members.
- Market perception remains mixed, as some analysts express doubts about the company's ability to deliver on its promises amid industry volatility.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
QTTB Latest News
-
12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga · May 28, 2026
-
12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga · May 27, 2026
-
Top Midday Gainers
MT Newswires · May 27, 2026
-
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga · May 27, 2026
QTTB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for QTTB.
Price Targets
Consensus target: $13.00
QTTB MoonshotScore
What does this score mean?
The MoonshotScore rates QTTB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Latest Q32 Bio Inc. Analysis
Leadership: Jodie Pope Morrison
CEO
Jodie Pope Morrison serves as the Chief Executive Officer of Q32 Bio Inc. Her career spans various leadership roles within the biotechnology and pharmaceutical industries. She brings extensive experience in strategic planning, business development, and commercialization of innovative therapies. Her background includes significant contributions to the advancement of clinical-stage programs and the successful launch of pharmaceutical products. She is responsible for managing 28 employees.
Track Record: Under Jodie Pope Morrison's leadership, Q32 Bio Inc. has focused on advancing its clinical pipeline, particularly ADX-097 and Bempikibart. Key milestones include the completion of Phase I clinical trials for ADX-097 and the progression of Bempikibart into Phase II trials. Her strategic decisions have shaped the company's focus on autoimmune and inflammatory diseases.
What Investors Ask About Q32 Bio Inc. (QTTB) — Healthcare
What does Q32 Bio Inc. do?
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologic therapeutics for autoimmune and inflammatory diseases. The company's pipeline includes ADX-097, a humanized anti-C3d monoclonal antibody fusion protein targeting complement-mediated diseases, and Bempikibart (ADX-914), a fully human anti-interleukin-7 receptor alpha antagonist monoclonal antibody in Phase II trials for atopic dermatitis and alopecia areata. Q32 Bio aims to restore healthy immune balance in patients by addressing pathological immune dysfunction.
What do analysts say about QTTB stock?
Analyst coverage of QTTB is limited, reflecting its clinical-stage status and smaller market capitalization. Key valuation metrics include its P/E ratio of 2.3 and high gross margin of 99.5%. Growth considerations center on the successful advancement of ADX-097 and Bempikibart through clinical trials and the potential for strategic partnerships. Analyst consensus is not readily available due to limited coverage, but potential investors should monitor clinical trial results and regulatory milestones.
What are the main risks for QTTB?
The primary risks for Q32 Bio Inc. include the inherent uncertainties of clinical-stage drug development, such as the potential for clinical trial failures or regulatory setbacks. Competition from larger pharmaceutical companies with greater resources poses a significant challenge. Additionally, the company's reliance on securing additional funding to support its research and development activities creates financial risk. Patent expiration and the emergence of biosimilar competition also represent long-term threats to its market position.
What are the key factors to evaluate for QTTB?
Q32 Bio Inc. (QTTB) holds an AI score of 65/100 (moderate). P/E: 2.3x vs the S&P 500's ~20-25x. Analysts target $13.00 (-4%). Not financial advice.
How frequently does QTTB data refresh on this page?
QTTB prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven QTTB's recent stock price performance?
Q32 Bio Inc. (QTTB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline of biologic therapeutics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider QTTB overvalued or undervalued right now?
Q32 Bio Inc. (QTTB) trades at 2.3x earnings. Analysts target $13.00 (-4%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying QTTB?
Before investing in Q32 Bio Inc. (QTTB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- Market projections are estimates and may not be accurate.